Ratings Exelixis, Inc.

Equities

EXEL

US30161Q1040

Real-time Estimate Cboe BZX Other stock markets 12:33:14 2024-05-09 pm EDT			5-day change	1st Jan Change
21.66 ^USD	+0.30%		-2.10%	-9.73%

May. 01	RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept	MT
Apr. 30	Exelixis Q1 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Maintained -- Shares Fall After Hours	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
EXELIXIS, INC.	-9.73%	6.29B	B
VERTEX PHARMACEUTICALS INCORPORATED	+2.62%	108B	B+
REGENERON PHARMACEUTICALS, INC.	+9.77%	105B	B+
ARGENX SE	+1.57%	23.46B	B
BIONTECH SE	-12.20%	21.72B	B+
GENMAB A/S	-7.05%	18.64B	A-
WUXI APPTEC CO., LTD.	-37.64%	17.45B	A-
BEIGENE, LTD.	-6.33%	17.19B	B
NEUROCRINE BIOSCIENCES, INC.	+6.13%	13.99B	C+
SAREPTA THERAPEUTICS, INC.	+35.09%	12.53B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes